Sign In
Buy VKTX
$32.37
+1.99 (+6.55%)
At Close: Jun 22, 2026
Ken Griffin started the Citadel hedge fund in 1990. It's become so successful that his net worth has risen to a stunning $46 billion.
3 Monster Stocks in the Making
06:30am, Saturday, 23'rd Nov 2024
3 Monster Stocks in the Making
Why Is Viking Therapeutics (VKTX) Down 29.5% Since Last Earnings Report?
12:36pm, Friday, 22'nd Nov 2024
Viking Therapeutics (VKTX) reported earnings 30 days ago. What's next for the stock?
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
11:00am, Friday, 22'nd Nov 2024
NEW YORK, NY / ACCESSWIRE / November 22, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are
VKTX Stock Loses Over $1B in a Month: How to Play the Stock?
10:21am, Friday, 22'nd Nov 2024
The plunge in Viking Therapeutics' share price can be attributed to the rising competition in the sector to secure a position in the booming obesity market.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
04:15pm, Wednesday, 20'th Nov 2024
NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ:VKTX). Such investors are
Viking Therapeutics Garners Analyst Support For NASH And Metabolic Programs
01:26pm, Wednesday, 20'th Nov 2024
On Tuesday, Viking Therapeutics, Inc. VKTX highlighted the final results from its VOYAGE Phase 2b trial of VK2809 in patients with biopsy-confirmed non-alcoholic steatohepatitis (NASH, also referred
Viking Therapeutics is more than just a weight-loss stock, and that's drawing cheers
12:06pm, Wednesday, 20'th Nov 2024
The biotech's liver-disease treatment is also viewed as best-in-class, earning it a full slate of buy ratings from analysts.
NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viking Therapeutics, Inc. ("Viking Therapeutics, Inc.") (NASDAQ:VKTX) conc
Oral Late Breaker Presentation Summarizes Positive Results Including Successful Achievement of Study's Primary and Secondary Endpoints Data Support VK2809's Best-in-Class Profile Highlighted by Robust
Did Viking Therapeutics, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - VKTX
10:15pm, Monday, 18'th Nov 2024
NEW YORK, NY / ACCESSWIRE / November 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viking Therapeutics, Inc. ("Viking Therapeutics, Inc.") (NASDAQ:VKTX) conc
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Viking Therapeutics, Inc. - VKTX
09:52pm, Monday, 18'th Nov 2024
NEW YORK , Nov. 18, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Viking Therapeutics, Inc. ("Viking" or the "Company") (NASDAQ: VKTX). Such investors are advis
NEW YORK, NY / ACCESSWIRE / November 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Viking Therapeutics, Inc. ("Viking Therapeutics, Inc.") (NASDAQ:VKTX) conc
3 Things You Need to Know if You Buy Viking Therapeutics Today
04:45am, Monday, 18'th Nov 2024
3 Things You Need to Know if You Buy Viking Therapeutics Today
Is It Too Late to Buy Viking Therapeutics Stock?
07:05am, Sunday, 17'th Nov 2024
Is It Too Late to Buy Viking Therapeutics Stock?
